What's on your mind?

There's both much to know and much to say and we'd like to hear from you; your ideas, your experiences... anything that helps provide perspective on lives that have been impacted by diseases of the central nervous system.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

NEWS

May 16, 2023

Cerevance Announces Oral Presentation of Phase 1 Data on CVN766 at American Society of Clinical Psychopharmacology (ASCP)

Cerevance today announced plans to present an oral presentation at the upcomingAmerican Society of Clinical Psychopharmacology (ASCP) conference, taking place in Miami, Florida, May 30 – June 2, 2023.

May 9, 2023

Cerevance Announces Presentation at Neurodegeneration: New Biology Guiding the Next Generation of Therapeutic Development

Cerevance today announced plans to present at the upcoming Neurodegeneration: New Biology Guiding the NextGeneration of Therapeutic Development conference, taking place in British Columbia,Canada, May 15 – 19, 2023.

May 8, 2023

Cerevance to Present at the 2023 RBC Capital Markets Global Healthcare Conference

Cerevance today announced that Craig Thompson, chief executive officer of Cerevance, will present at the upcoming 2023 RBC Capital Markets Global Healthcare Conference being held May 16-17, 2023. Company management will also be available for virtual one-on-one meetings.

April 13, 2023

Cerevance Announces Poster Presentation at the BNA International Festival of Neuroscience

Cerevance today announced a poster presentation at the British Neuroscience Association (BNA) 2023 International Festival of Neuroscience in Brighton, United Kingdom being held April 23-26, 2023

April 10, 2023

Cerevance to Present at the Needham Healthcare Conference

Cerevance today announced that Craig Thompson, chief executive officer of Cerevance, will present at the upcoming 22nd Annual Needham Healthcare Conference.

March 27, 2023

Cerevance to Participate in Chief Medical Officer Summit 360˚

Cerevance announced that Ottavio V. Vitolo, M.D., chief medical officer of Cerevance, will participate in a roundtable discussion at the upcoming Chief Medical Officer Summit 360˚ (CMO Summit 360˚).

March 21, 2023

Cerevance Announces Presentations at Two Medicinal Chemistry Conferences

Cerevance today announced plans to present at the Alzheimer’s Research UK Conference 2023, held in Aberdeen, Scotland and virtually from March 14-15, 2023.

March 20, 2023

Cerevance Announces Presentations at AD/PD™ 2023 International Conference

  • Positive CVN424 Phase 2 data for Parkinson’s disease to be presented
  • Presentation of NETSseq platform’s ability to reveal novel targets to inform CNS drug development
  • Novel target, CVN417, for the potential treatment of Parkinson’s disease to be disclosed
March 7, 2023

Cerevance Announces Upcoming Presentation at the Alzheimer’s Research UK Conference 2023

Cerevance today announced plans to present at the Alzheimer’s Research UK Conference 2023, held in Aberdeen, Scotland and virtually from March 14-15, 2023.

February 13, 2023

Cerevance Expands Series B Financing with Additional $51 Million

  • Proceeds will advance Cerevance’s potential first-in-class programs developed using proprietary NETSseq platform
  • CVN424 for Parkinson’s disease will advance to Phase 2 monotherapy study in Q2 2023
  • CVN766 for negative and cognitive symptoms of schizophrenia will advance to Phase 2 study in Q4 2023
  • CVN293 for Amyotrophic Lateral Sclerosis will advance to Phase 1 study in Q3 2023
January 27, 2023

Cerevance Announces Publication in Organic Process Research and Development

Cerevance today announced the publication in Organic Process Research and Development entitled, “Scalable Synthesis of CVN424, an Inverse Agonist of the GPR6 Receptor”.

January 24, 2023

Cerevance to Participate at the SVB Global Biopharma Conference

Cerevance, today announced that Craig Thompson, chief executive officer of Cerevance, will participate in the upcoming SVB Global Biopharma Conference.